The draft paper on the quality review of documentssubmitted for consultation by the EMA does not reflect the spirit of the new pharmacovigilance legislation, which is to prevent druginduced harm.
Category: Publications
Access to EU Institutions’ documents is essential to advance trasparency and to serve public health
EU Parliament says no and no again to EMA: Independent groups echo decision
Pharmacovigilance data
Broadening access to signal is a positive step, but access to VigiBase is also needed
read (161 KB)
Newsletter December 2011
Attachment: aaisbdnewsletter_dec2011_full.pdf